

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

### **石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1093)**

### **INSIDE INFORMATION**

#### **INDICATIVE RESULTS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2020**

This announcement is made by CSPC Pharmaceutical Group Limited (the “**Company**”) pursuant to Rules 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

CSPC Innovation Pharmaceutical Co., Ltd. (石藥集團新諾威製藥股份有限公司) (“**CSPC XNW**”) is a subsidiary of the Company and its shares are listed on the ChiNext of Shenzhen Stock Exchange (Stock Code: 300765). In compliance with the relevant applicable requirements of Shenzhen Stock Exchange, CSPC XNW published an announcement on its indicative results for the three months ended 31 March 2020 (“**Indicative Announcement**”) on the information disclosure webpage of Shenzhen Stock Exchange’s website at <http://www.szse.cn/disclosure/listed/notice/index.html>.

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the appendix of this announcement (the “**Appendix**”) which set out the Indicative Announcement prepared by CSPC XNW in accordance with the PRC Accounting Standard for Business Enterprises.

Please note that the Indicative Announcement in the Appendix was originally prepared by CSPC XNW in Chinese language. In case of any inconsistency between the Chinese version and the English versions, the Chinese version shall prevail.

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**Cai Dongchen**  
*Chairman*

Hong Kong, 23 March 2020

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.*

## APPENDIX

Stock Code: 300765

Stock Name: XNW

Ref. No.: 2020-022

### CSPC INNOVATION PHARMACEUTICAL CO., LTD. INDICATIVE RESULTS FOR THE FIRST QUARTER OF 2020

The company and all members of its board warrant that the information disclosed is true, accurate and complete, and does not contain any false statements, misleading representations or material omissions.

#### I. Indicative results for the current period

1. Period for the indicative results: 1 January 2020 to 31 March 2020
2. Indicative Results:  Loss  Turnaround  Increase over the  Decrease over the  
from loss same period same period  
last year last year

Item	Current reporting period	Same period last year
Net profit attributable to the shareholders of the listed company	Increased by 15% to 30% as compared with the same period last year	Profit: 5,644.86 (in Ten Thousand Yuan)
	Profit: 6,491.59 to 7,338.31 (in Ten Thousand Yuan)	

Note: "Ten Thousand Yuan" in the table denotes ten thousand Renminbi.

#### II. Preliminary audit of the indicative results

The financial data related to the indicative results has not been audited by certified public accountants.

#### III. Explanation for the changes in results

1. During the reporting period, on the basis of taking adequate preventive and control measures against the novel coronavirus pneumonia outbreak, the company strived to ensure the normal production and operation. It is expected that the results will increase over the same period last year.
2. The anticipated impact of the non-recurring gain/loss on the current net profit for the reporting period will be approximately RMB600 to RMB1,000 (in Ten Thousand Yuan).

#### **IV. Other relevant explanation**

The data set out in the indicative results is based on the preliminary estimation by the finance department of the company and has not been audited by any auditing firm. The specific results data in detail should be those disclosed in the company's report for the first quarter of 2020. Investors are advised to make cautious decision and pay attention to the investment risks involved.

Announcement is hereby made.

*The board of directors of*  
**CSPC Innovation Pharmaceutical Co., Ltd.**  
23 March 2020